Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5270753
Max Phase: Preclinical
Molecular Formula: C40H68O14
Molecular Weight: 772.97
Associated Items:
ID: ALA5270753
Max Phase: Preclinical
Molecular Formula: C40H68O14
Molecular Weight: 772.97
Associated Items:
Canonical SMILES: CO[C@@H]1[C@@H](O)[C@H](OC[C@@H](CC[C@@H](C)[C@H]2[C@@H](O)[C@H](O)[C@@H]3[C@]2(C)CC[C@H]2[C@@]3(O)C[C@@H](O)C3=C[C@@H](O[C@@H]4OC[C@@H](O)[C@H](O)[C@H]4OC)CC[C@@]32C)C(C)C)OC[C@H]1O
Standard InChI: InChI=1S/C40H68O14/c1-19(2)21(16-51-36-32(47)33(49-6)26(43)18-52-36)9-8-20(3)28-30(45)31(46)35-39(28,5)13-11-27-38(4)12-10-22(14-23(38)24(41)15-40(27,35)48)54-37-34(50-7)29(44)25(42)17-53-37/h14,19-22,24-37,41-48H,8-13,15-18H2,1-7H3/t20-,21-,22+,24-,25-,26-,27-,28+,29+,30-,31+,32-,33+,34-,35-,36-,37+,38+,39-,40+/m1/s1
Standard InChI Key: KXIPJTRVDXJRTI-AHVCBUDKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 772.97 | Molecular Weight (Monoisotopic): 772.4609 | AlogP: 0.87 | #Rotatable Bonds: 12 |
Polar Surface Area: 217.22 | Molecular Species: NEUTRAL | HBA: 14 | HBD: 8 |
#RO5 Violations: 3 | HBA (Lipinski): 14 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.18 | CX Basic pKa: | CX LogP: 0.40 | CX LogD: 0.40 |
Aromatic Rings: 0 | Heavy Atoms: 54 | QED Weighted: 0.13 | Np Likeness Score: 2.41 |
1. Sasayama Y, Mamiya T, Qi J, Shibata T, Uchida K, Nabeshima T, Ojika M.. (2023) Neuritogenic steroid glycosides from crown-of-thorns starfish: Possible involvement of p38 mitogen-activated protein kinase and attenuation of cognitive impairment in senescence-accelerated mice (SAMP8) by peripheral administration., 78 [PMID:36577328] [10.1016/j.bmc.2022.117144] |
Source(1):